The following is a summary of the Delcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Delcath Systems reported Q1 revenue of $3.1 million including $2 million from HEPZATO sales and $1.1 million from CHEMOSAT.

• Achieved an effective gross margin of approximately 60% in the first quarter.

• Reported research and development expenses decreased to $3.7 million compared to $4.7 million for the same period in 2023.

• Selling, general, and administrative expenses increased to $8.8 million from $4.2 million.

• The company ended the first quarter with cash investments totaling $27.2 million.

Business Progress:

• Now reporting U.S revenue for the first time with six treatment centers actively providing commercial treatments.

• Overall number of engaged centers increased to 30 and aims to have 20 active centers by the end of 2024.

• Plans to initiate clinical trials of HEPZATO in other tumor types within a year.

• Aims to achieve $10 million in quarterly revenue in the U.S in 2024, with European growth primarily driven by Germany.

• Plans to open more treatment sites, promote patient referrals, and cater to half of the patient base with 25-35 centers.

• Anticipating growth in patient referrals from oncologists in the next 6-12 months and seeks additional reimbursement from private payers.

• Plans to hire a representative in the U.K in expectation of potential insurance reimbursements there.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.